Langley RG,Elewski BE,Lebwohl M,Reich K,Griffiths C,Papp K .2014 .FIXTURE study groups. N Engl J Med, 371(4) : 326-38.
Griffiths CE,Barker JN .2007 .Pathogenesis and clinical features of psoriasis. Lancet, 370 : 263-71.
Raharja A,Mahil SK,Barker JN .2021 .Psoriasis: a brief overview. Clin Med (Lond), 21(3) : 170-3.
Jacobson CC,Kumar S,Kimball AB .2011 .Latitude and psoriasis prevalence. J Am Acad Dermatol, 65(4) : 870-3.
Park H,Li Z,Yang XO,Chang SH,Nurieva R,Wang YH .2005 .A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6(11) : 1133-41.
Harrington LE,Hatton RD,Mangan PR,Turner H,Murphy TL,Murphy KM .2005 .Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6(11) : 1123-32.
Girolomoni G,Mrowietz U .2012 .Psoriasis: rationale for targeting interleukin17. Br J Dermatol, 167(4) : 717-24.
Ejaz A,Suhail M,Iftikhar A .2013 .Psoriasis in Pakistani population: Associations, comorbidities, and hematological profile. J Pak Assoc Dermatol, 23(1) : 42-6.
Lu Y,Chen H,Nikamo P,Low HQ,Helms C,Seielstad M .2013 .Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol, 133(3) : 836-9.
Rebora A .2007 .Conventional therapies for psoriasis. Reumatismo, 59(1) : 77-80.
Rich SJ,Bello-Quintero CE .2004 .Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm, 10(4) : 318-25.
Gisondi P,Vedove CD,Girolomoni G .2014 .Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy. Dermatol Ther (Heidelb), 4(1) : 1-9.
Sanford M,McKeage K. Secukinumab M .2015 .: first global approval. Drugs, 75(3) : 329-38.
Topal IO,Baysak S,Altunay IK,Polat AK,Arikan EE,Ozkur E .2022 .Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-tosevere psoriasis: real-world data from a retrospective multicenter study. An Bras Dermatol, 97(5) : 566-74.
Alexander A,Navarini MD,Poulin Y,Menter A,Yihua Gu MS,Teixeira HD .2014 .Analysis of body region and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol, 13(5) : 554-62.
Finlay AY,Khan GK .1994 .Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol, 19(3) : 210-16.
Yan Zhao,Lin Cai,Xiao-Yang Liu .2021 .Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study. Chin Med J (Engl), 134(11) : 1324-8.
Neema S,Radhakrishnan S,Singh S,Vasudevan B,Chatterjee M .2019 .Real-life efficacy and safety of secukinumab: A single-center, retrospective observational study with 52-week follow-up. Indian J Drugs Dermatol, 5(6) : 14.
Lin Cai,Jian-Zhong Shang,Yao Xu .2020 .Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinses patients with moderate to severe plaque psoriasis. Chinese Med, 133(22) : 2665.
Tariq H,Basharat M,Javed S,Aman S. Efficacy .2022 .and safety of secukinumab in treatment of moderate to severe psoriasis. J Pak Assoc Dermatol, 32(1) : 9-14.
Momose M,Asahina A,Umezawa Y,Nakagawa H Y .2018 .Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience. J Dermatol, 45(3) : 318-21.
Rich P,Sigurgeirsson B,Thaci D,Ortonne JP,Paul C,Schopf RE .2013 .Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebocontrolled, phase II regimen-finding study. Br J Dermatol, 168(2) : 402-11.
Pariser D,Frankel E,Schlessinger J,Poulin Y,Vender R,Langley RG,Ther RG .2018 .Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. , 8(1) : 17-32.
Huang W,Na L,Fidel PL,Schwarzenberger P .2004 .Requirement of interleukin-17A for systemic anit-Candida albicans host defense in mice. J Infect Dis, 190(3) : 624-31.
Papp KA,Langley RG,Sigurgeirsson B,Abe M,Baker DR,Konno P .2013 .Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebocontrolled phase II dose-ranging study. Br J Dermatol, 168(2) : 412-21.